Evidence map›Paper›PMID 36413635›Full record

ArticleClinical cardiology2023

A multicenter prospective randomized study comparing the incidence of periprocedural cerebral embolisms caused by catheter ablation of atrial fibrillation between cryoballoon and radiofrequency ablation (Embo-Abl study): Study design.

Koji Miyamoto, Koshiro Kanaoka, Yasutoshi Ohta, Masue Yoh, Hiroki Takahashi, Rena Tonegawa-Kuji, Yuichiro Miyazaki, Keiko Shimamoto, Akinori Wakamiya, Nobuhiko Ueda and 14 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Clinical cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 1 country.

Koji MiyamotoDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Koshiro KanaokaCenter for Cerebral and Cardiovascular Disease Information, Open Innovation Center, National Cerebral and Cardiovascular Center, Suita, Japan.
Yasutoshi OhtaDepartment of Radiology, National Cerebral and Cardiovascular Center, Suita, Japan.
Masue YohDepartment of Medicine II, Kansai Medical University, Moriguchi, Japan.
Hiroki TakahashiDepartment of Medicine II, Kansai Medical University, Moriguchi, Japan.
Rena Tonegawa-KujiCenter for Cerebral and Cardiovascular Disease Information, Open Innovation Center, National Cerebral and Cardiovascular Center, Suita, Japan.
Yuichiro MiyazakiDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Keiko ShimamotoDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Akinori WakamiyaDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Nobuhiko UedaDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Kenzaburo NakajimaDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Tsukasa KamakuraDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Mitsuru WadaDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Kohei IshibashiDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Yuko InoueDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Satoshi NagaseDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Takeshi AibaDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Akihisa NaraiNew Development Group, Hashimoto Electronic Industry Co., Ltd, Matsusaka, Japan.
Tomohiro NakaseNew Development Group, Hashimoto Electronic Industry Co., Ltd, Matsusaka, Japan.
Masatoshi KogaDepartment of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Tetsuya FukudaDepartment of Radiology, National Cerebral and Cardiovascular Center, Suita, Japan.
Naoya KataokaSecond Department of Internal Medicine, University of Toyama, Toyama, Japan.
Masahiko TakagiDepartment of Medicine II, Kansai Medical University, Moriguchi, Japan.ORCID http://orcid.org/0000-0001-7712-8529
Kengo KusanoDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.ORCID http://orcid.org/0000-0002-5760-9285
National Cerebral and Cardiovascular Center · JPKansai Medical University · JPHashimoto Municipal Hospital · JPUniversity of Toyama · JP

Funding

Intramural
6 · The paper itself

Abstract

backgroundAlthough catheter ablation (CA) has become a standard therapeutic approach to atrial fibrillation (AF), it imposes a low but relevant risk of thromboembolic complications of around 0.5%-1%, including ischemic strokes, and has an additional risk of clinically silent cerebral embolisms (SCEs) of 10%-40%. Both cryoballoon (CB) and radiofrequency (RF) ablation are routinely used clinically worldwide, yet there are few prospective data comparing the incidence of cerebral embolism after CA of AF between CB and RF ablation.

methodsThe aim of the Embo-Abl study will be to compare the incidence of cerebral embolisms on 3 T diffusion-weighted image magnetic resonance imaging (MRI) after CA of AF between CB and RF ablation in patients with AF in a prospective, multicenter, open-label, controlled, randomized fashion. The primary endpoint of the Embo-Abl study will be the occurrence of MRI-detected SCE 1-3 days after CA. The patients will be registered and randomly assigned to either the CB or RF ablation group in a 1:1 ratio. The study cohort will include 230 patients with AF from a multicenter in Japan.

resultsThe results of this study are currently under investigation.

conclusionThe Embo-Abl study will be the first to compare the incidence of periprocedural cerebral embolisms caused by CA of AF between CB and RF ablation in a prospective, multicenter, randomized, controlled fashion.

Indexed as

Atrial FibrillationCatheter AblationCryosurgeryEmbolismIntracranial EmbolismPulmonary VeinsHumansIncidenceMulticenter Studies as TopicProspective StudiesRandomized Controlled Trials as TopicRecurrenceRisk FactorsTreatment Outcomeatrial fibrillationcerebral embolismcryoballoon ablationradiofrequency ablation

Identifiers

PMID36413635
PMCPMC9933100
OpenAlexW4309620812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.